| Patient | Joe Louis |
|---|---|
| Date of birth | 1971-05-13 |
| Identifiers | MRN HR-BX002-SYN; SSN (made up) 000-02-6639 |
| Document date | 2026-11-01 |
| Author | Desmond Achterberg-Cole, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for persecutory thoughts and poor sleep two weeks after a collapse in the street: a nonjudgmental assessment of cocaine use, the differential of psychosis, a cognitive screen, safety, cardiovascular risk, harm reduction and money worries. Concerns: He feels he is being followed and cannot sleep, and wants to feel like himself again; He is worried about his heart and his mind after collapsing in the street; He worries about money and does not want his family burdened. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with fentanyl test strips and instruction for him and anyone he lives with | One spray as needed for suspected overdose; repeat in 2 to 3 minutes if needed | Nasal route | 2026-07-13 | active | S |
| Aripiprazole 5 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-07-20 to 2026-09-21 | completed | S |
| Aripiprazole 2 mg oral tablet, one tablet each morning for two weeks, then stop | One tablet each morning for two weeks, then stop | Oral route | 2026-09-21 to 2026-10-05 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-08-10 | active | S |
| Sodium chloride 0.65% nasal spray, two sprays in each nostril as needed for congestion | Two sprays in each nostril up to every 4 hours as needed | Nasal route | 2026-08-03 to 2026-08-08 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for sore throat or aches, no more than 3,000 mg a day | One or two tablets every 6 hours as needed, no more than 3,000 mg a day | Oral route | 2026-08-03 to 2026-08-08 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Resting 12-lead electrocardiogram: sinus tachycardia at 102 per minute, left ventricular hypertrophy by voltage criteria, no ischemic changes, QTc 436 ms | 2026-07-13 to 2026-07-13 | completed | S |
| MRI of the brain without contrast: no contusion, microbleeds or mass; brain volume normal for age | 2026-07-20 to 2026-07-20 | completed | S |
| Transthoracic echocardiogram: ejection fraction 60%, mild concentric left ventricular hypertrophy, normal valves, aortic root 3.6 cm and ascending aorta 3.5 cm | 2026-09-21 to 2026-09-21 | completed | S |
| Advance care planning conversation, about 18 minutes | 2026-09-14 to 2026-09-14 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-09-14 | Influenza vaccine, standard dose, for the coming season | completed | S |
| 2026-09-14 | Tdap vaccine; last tetanus booster more than ten years ago | completed | S |
| 2026-09-14 | Pneumococcal conjugate vaccine (PCV20), recommended for all adults aged 50 and older | completed | S |
| 2026-09-14 | Hepatitis B vaccine (HepB-CpG), first of two doses; not immune at intake | completed | S |
| 2026-09-14 | Hepatitis A vaccine, adult, first of two doses, recommended for people who use drugs | completed | S |
| 2026-10-26 | Hepatitis B vaccine (HepB-CpG), second of two doses | completed | S |
| 2026-10-26 | Recombinant zoster vaccine, first of two doses | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1930s to 1940s | Professional boxing career of 71 bouts, 68 won and 54 by knockout, with the heavyweight championship held from 1937 until he retired as champion in 1949 | D (CLM-0003, CLM-0013) |
| 1942 to 1945 | U.S. Army service in the Second World War | D (CLM-0004) |
| late June 1969 | Collapse on a street in New York, hospitalized for what was described as a physical breakdown; he later attributed it to cocaine use | D (CLM-0006) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He feels he is being followed and cannot sleep, and wants to feel like himself again | active | S |
| He is worried about his heart and his mind after collapsing in the street | active | S |
| He worries about money and does not want his family burdened | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 7.6 on 2026-07-13; Hemoglobin [Mass/volume] in Blood 14.8 on 2026-07-13; MCV [Entitic mean volume] in Red Blood Cells by Automated count 90 on 2026-07-13; Platelets [#/volume] in Blood by Automated count 236 on 2026-07-13; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-10-26; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-10-26; Creatinine [Mass/volume] in Serum or Plasma 1.12 on 2026-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 78 on 2026-10-26; Glucose [Mass/volume] in Serum or Plasma 92 on 2026-10-26; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 2026-07-13; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 33 on 2026-07-13; Creatine kinase [Enzymatic activity/volume] in Serum or Plasma 262 on 2026-07-13; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-07-13; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 486 on 2026-07-13; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-07-13; Total score [DAST-10] 7 on 2026-07-13; Total score [AUDIT-C] 3 on 2026-07-13; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-10-26; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 4 on 2026-10-26; Total score [MoCA] 27 on 2026-09-21; Cholesterol [Mass/volume] in Serum or Plasma 204 on 2026-07-20; Cholesterol in HDL [Mass/volume] in Serum or Plasma 44 on 2026-07-20; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 on 2026-07-20; Triglyceride [Mass/volume] in Serum or Plasma 160 on 2026-07-20; Albumin/Creatinine [Mass Ratio] in Urine 14 on 2026-08-10; Left ventricular Ejection fraction 60 on 2026-09-21; Prostate specific Ag [Mass/volume] in Serum or Plasma 1.3 on 2026-09-14; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-14 [S]
Strengths and supports: Strengths and supports: the discipline of a long athletic career, generosity toward others, pride in his Army service and in what his career meant to many people, a quiet dignity and humor, friends from boxing and the Army, and his own decision to come in after the collapse [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Persecutory thoughts and poor sleep for about two months: a fixed belief that people are following him and plan to harm him, three to four hours of sleep a night, partial insight; cause under evaluation | resolved | confirmed | R41.89 | S — Synthetic presenting problem anchored to his documented fears of a plot against his life; resolved into the diagnosis at the consultation. Not a claim about his real symptoms. |
| Cocaine use disorder, severe (seven of eleven DSM-5-TR criteria): intranasal cocaine most days for about a year, last use three days before intake | resolved | confirmed | F14.20 | S — Synthetic modern coding at intake; superseded at the consultation by the combined code once the psychotic disorder was diagnosed. Person-first language; not a claim about his real diagnosis. |
| Cocaine use disorder, severe, with cocaine-induced psychotic disorder (persecutory delusions during heavy use, persisting ten days after the last use, with no history of psychosis off cocaine, a normal examination and no evidence of a neurocognitive disorder); psychotic symptoms resolved within four weeks on aripiprazole | active | confirmed | F14.250 | S — Synthetic modern diagnosis made at the consultation. Not a claim about his real diagnosis. |
| Raised blood pressure at intake (154/98 mmHg) three days after cocaine use, without a diagnosis of hypertension; home readings planned | resolved | confirmed | R03.0 | S — Synthetic presenting finding; resolved into a diagnosis of hypertension at four weeks. |
| Hypertension, stage 2, confirmed four weeks after the last cocaine use (clinic 146/92, home average 144/90 mmHg), with mild concentric left ventricular hypertrophy and a normal aortic root on echocardiography; treated with amlodipine | active | confirmed | I10 | S — Synthetic modern diagnosis made at the four-week visit. |
| Financial insecurity: years of tax debt from his time as a well-paid athlete, now settled, left him with no savings; irregular income from paid appearances; worry about money keeps him awake | active | confirmed | Z59.86 | S — Synthetic social need anchored to his documented tax debt. |
| Acute viral upper respiratory infection (common cold) for three days; rapid tests negative for influenza and COVID-19; resolved within ten days without antibiotics | resolved | confirmed | J06.9 | S — Synthetic acute illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-13 | Leukocytes [#/volume] in Blood by Automated count | 7.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-13 | Hemoglobin [Mass/volume] in Blood | 14.8 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-07-13 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 90 | fL | 80-100 fL | Normal | S |
| 2026-07-13 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-13 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.16 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 74 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-13 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-07-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 10-40 U/L | Normal | S |
| 2026-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 7-56 U/L | Normal | S |
| 2026-07-13 | Creatine kinase [Enzymatic activity/volume] in Serum or Plasma | 262 | U/L | 39-308 U/L | Normal | S |
| 2026-07-13 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-07-13 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 486 | pg/mL | 200-900 pg/mL | Normal | S |
| 2026-07-13 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2026-07-13 | Total score [DAST-10] | 7 | {score} | S | ||
| 2026-07-13 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 2026-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-07-13 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 2026-07-13 | Total score [MoCA] | 25 | {score} | S | ||
| 2026-07-20 | Cholesterol [Mass/volume] in Serum or Plasma | 204 | mg/dL | <=199 mg/dL | High | S |
| 2026-07-20 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-07-20 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 | mg/dL | <=99 mg/dL | High | S |
| 2026-07-20 | Triglyceride [Mass/volume] in Serum or Plasma | 160 | mg/dL | <=149 mg/dL | High | S |
| 2026-08-10 | Albumin/Creatinine [Mass Ratio] in Urine | 14 | mg/g{creat} | <=29 mg/g{creat} | Normal | S |
| 2026-08-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-08-10 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S | ||
| 2026-09-21 | Left ventricular Ejection fraction | 60 | % | 52-72% | Normal | S |
| 2026-09-21 | Total score [MoCA] | 27 | {score} | S | ||
| 2026-09-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-10-26 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.12 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 78 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-26 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-10-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S | ||
| 2026-09-14 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 1.3 | ng/mL | <=4 ng/mL | Normal | S |
| 2026-09-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-13 | Body height | 187 | cm | S |
| 2026-07-13 | Body weight | 101.2 | kg | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 28.9 | kg/m2 | S |
| 2026-07-13 | Systolic blood pressure | 154 | mm[Hg] | S |
| 2026-07-13 | Diastolic blood pressure | 98 | mm[Hg] | S |
| 2026-07-13 | Heart rate | 102 | /min | S |
| 2026-07-13 | Respiratory rate | 16 | /min | S |
| 2026-07-13 | Body temperature | 36.9 | Cel | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-20 | Body height | 187 | cm | S |
| 2026-07-20 | Body weight | 101 | kg | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 28.9 | kg/m2 | S |
| 2026-07-20 | Systolic blood pressure | 148 | mm[Hg] | S |
| 2026-07-20 | Diastolic blood pressure | 94 | mm[Hg] | S |
| 2026-07-20 | Heart rate | 90 | /min | S |
| 2026-07-20 | Respiratory rate | 16 | /min | S |
| 2026-07-20 | Body temperature | 36.8 | Cel | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-10 | Body height | 187 | cm | S |
| 2026-08-10 | Body weight | 101.8 | kg | S |
| 2026-08-10 | Body mass index (BMI) [Ratio] | 29.1 | kg/m2 | S |
| 2026-08-10 | Systolic blood pressure | 146 | mm[Hg] | S |
| 2026-08-10 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-08-10 | Heart rate | 82 | /min | S |
| 2026-08-10 | Respiratory rate | 16 | /min | S |
| 2026-08-10 | Body temperature | 36.7 | Cel | S |
| 2026-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-21 | Body height | 187 | cm | S |
| 2026-09-21 | Body weight | 102.1 | kg | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 29.2 | kg/m2 | S |
| 2026-09-21 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-09-21 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-09-21 | Heart rate | 74 | /min | S |
| 2026-09-21 | Respiratory rate | 16 | /min | S |
| 2026-09-21 | Body temperature | 36.6 | Cel | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-26 | Body height | 187 | cm | S |
| 2026-10-26 | Body weight | 101.6 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 29.1 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 72 | /min | S |
| 2026-10-26 | Respiratory rate | 16 | /min | S |
| 2026-10-26 | Body temperature | 36.7 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-14 | Body height | 187 | cm | S |
| 2026-09-14 | Body weight | 102 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 29.2 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 76 | /min | S |
| 2026-09-14 | Respiratory rate | 16 | /min | S |
| 2026-09-14 | Body temperature | 36.6 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-03 | Body height | 187 | cm | S |
| 2026-08-03 | Body weight | 101.4 | kg | S |
| 2026-08-03 | Body mass index (BMI) [Ratio] | 29 | kg/m2 | S |
| 2026-08-03 | Systolic blood pressure | 146 | mm[Hg] | S |
| 2026-08-03 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-08-03 | Heart rate | 90 | /min | S |
| 2026-08-03 | Respiratory rate | 16 | /min | S |
| 2026-08-03 | Body temperature | 37.6 | Cel | S |
| 2026-08-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-07-13 | Establishing primary care for persecutory thoughts and poor sleep two weeks after a collapse in the street: a nonjudgmental assessment of cocaine use, the differential of psychosis, a cognitive screen, safety, cardiovascular risk, harm reduction and money worries | finished | S |
| 2026-07-20 | One-week review, seen the same day by addiction psychiatry: the diagnosis, an antipsychotic, contingency management and cognitive behavioral therapy | finished | S |
| 2026-08-10 | Four-week review: psychotic symptoms, urine tests, blood pressure and a diagnosis of hypertension | finished | S |
| 2026-09-21 | Ten-week review: remission, the antipsychotic taper, cognition off cocaine, the echocardiogram and a one-day return to use | finished | S |
| 2026-10-26 | Fifteen-week review off the antipsychotic: recovery, blood pressure and finances | finished | S |
| 2026-09-14 | Periodic adult preventive visit | finished | S |
| 2026-08-03 | Same-day sick visit for a cold | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| A nonjudgmental assessment: DSM-5-TR criteria, the DAST-10 and AUDIT-C, and a urine drug test (with fentanyl) done only with his consent and explained as part of care; person-first language; his own goals first | completed | GL-ASAM-STUD-2023, GL-SAMHSA-TIP33-2021, GL-USPSTF-DRUG-2020 | S |
| Addiction psychiatry consultation to settle the diagnosis, advise on an antipsychotic and plan treatment for cocaine use disorder | completed | GL-ASAM-STUD-2023, GL-APA-SCZ-2020 | S |
| Differential diagnosis of the psychotic symptoms: follow their course after the last cocaine use; MoCA now and again when he is well; TSH, vitamin B12, HIV and syphilis tests; brain MRI because the symptoms are new after age 50 in a man with years of head impacts; traumatic encephalopathy syndrome is a research diagnosis with no clinical test, and no such label is given; a structured assessment that guards against the documented bias toward diagnosing schizophrenia in Black men | completed | GL-APA-SCZ-2020, GL-TES-2021, GL-DISPARITY-2014 | S |
| Safety: a structured safety assessment, a written safety plan, the 988 Suicide & Crisis Lifeline saved in his phone, written criteria for urgent care, and safety review at every visit | completed | GL-SUICIDE-2024, GL-CMID-2026 | S |
| Harm reduction: fentanyl can be in cocaine; naloxone nasal spray and fentanyl test strips, never using alone, and the clinic's open door after any use | completed | GL-ASAM-STUD-2023, GL-SAMHSA-NALOXONE | S |
| Aripiprazole 5 mg daily for persecutory beliefs that persist after ten days without cocaine; weight, blood pressure, glucose and lipids, akathisia and movement checks under the APA guideline; a gradual taper after a period of remission | completed | GL-APA-SCZ-2020, GL-ASAM-STUD-2023 | S |
| Contingency management with twice-weekly urine tests for twelve weeks and prize draws for negative results, with weekly cognitive behavioral therapy; no medicine is approved by the FDA for cocaine use disorder, and off-label medicines are held back while he does well, since the stimulant-based ones are unsafe after psychosis and with high blood pressure | completed | GL-ASAM-STUD-2023, GL-SAMHSA-TIP33-2021 | S |
| Cardiovascular risk from cocaine: ECG and creatine kinase today; blood pressure at every visit and a home monitor with twice-daily readings for a week before the four-week visit; call 911 for chest pain, shortness of breath, weakness or tearing pain in the chest or back; beta-blockers avoided while he may still use cocaine | completed | GL-ASAM-STUD-2023, GL-AHA-HTN-2025 | S |
| Hypertension: amlodipine 5 mg daily with a target below 130/80 mmHg; urine albumin; an echocardiogram for left ventricular hypertrophy that also measures the aortic root and ascending aorta; abdominal aortic ultrasound not indicated before 65 in a man who has never smoked | completed | GL-AHA-HTN-2025, GL-CMID-2026, GL-USPSTF-AAA-2019 | S |
| Money worries: the clinic social worker helps with a budget, benefits he may qualify for as a veteran, and a free review of his tax records by a Low Income Taxpayer Clinic, with the Taxpayer Advocate Service if any federal tax problem is found | completed | GL-LITC, GL-TAS | S |
| Family involvement only with his consent: he chooses whom, if anyone, to involve and what may be shared; the clinic contacts no one without his permission unless his life is in danger | completed | GL-APA-SCZ-2020 | S |
| Sleep: regular hours, no cocaine and little alcohol, light in the morning and a dark room at night; no sleeping pill while he may use cocaine or alcohol | completed | GL-ASAM-STUD-2023 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Persecutory fears gone and six or more hours of sleep | 2026-08-10 | completed | No persecutory beliefs by four weeks; sleeping six to seven hours | S |
| No cocaine use, his goal, with contingency management and cognitive behavioral therapy | 2026-10-26 | active | No use for six weeks, one day of use at week seven reported by him, none since; 22 of 24 scheduled urine tests done, 21 negative | S |
| Blood pressure below 130/80 mmHg | 2026-10-26 | completed | 154/98 at intake, 146/92 at diagnosis, 126/78 on amlodipine | S |
| A clear answer about his memory and thinking once he is well | 2026-09-21 | completed | MoCA 25 during symptoms, 27 after ten weeks; brain MRI normal; no neurocognitive disorder | S |
| A plan for money that lets him sleep | 2026-10-26 | completed | Budget made with the social worker; a free tax clinic review confirmed no money owed; benefits checked | S |
Structured synthetic safety assessment on 2026-07-13: current ideation absent, intent absent, plan absent. Outpatient care with weekly visits and a phone check in three days. He has persecutory beliefs but no thoughts of suicide or of harming anyone, no command hallucinations, no plan to act against the people he fears, and he is caring for himself, so he does not need hospital care now; criteria for urgent care were written down with him (thoughts of harming himself or anyone else, acting on the fears, hallucinations, confusion, chest pain or not sleeping at all for two nights). Risk factors reviewed: cocaine use, persecutory beliefs, poor sleep, money worries and a recent collapse. No firearms in the home. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in his phone. Safety is reviewed at every visit [S]